X-396 Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03215693
Recruitment Status : Unknown
Verified December 2017 by Betta Pharmaceuticals Co., Ltd.. Recruitment status was: Recruiting
The main purpose of the study is to evaluate safety and efficacy of X-396(Ensartinib) capsule in patients with ALK-positive non-small cell lung cancer previously treated with crizotinib.While exploring the relationship between biomarkers and drug efficacy and safety.
Condition or disease
Non-Small Cell Lung Cancer
Drug: X-396 capsule
This is a phase II, multicenter, single-arm study in which the safety and efficacy of X-396(Ensartinib) will be assessed in adult Chinese patients with ALK-positive(rearrangement) non-small cell lung cancer previously treated with crizotinib. Approximately 144 patients with locally advanced or metastatic NSCLC which carry ALK -rearrangement will be enrolled in the study.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Histologically or cytologically confirmed diagnosis of metastatic non-small cell lung cancer.
Evidence of positive ALK.
Patients must have demonstrated progression during or after crizotinib treatment.
Age 18 years or older at the time of informed consent.
Eastern cooperative oncology group performance status (ECOG PS) of 0-2
Measurable disease by response evaluation criteria in solid tumors (RECIST) version 1.1 (v1.1).
Asymptomatic CNS metastases do not require the use of steroids or anticonvulsants.
Willingness and ability to comply with the trial and follow-up procedures.
Ability to understand the nature of this trial and give written informed consent.
Prior use of ALK TKIs with the exception of crizotinib.
Patients currently receiving cancer system therapy.
Use of an investigational drug within 4 weeks prior to the first dose of study drug.
Presence of active gastrointestinal (GI) disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of study medications.
Patients with a known allergy or delayed hypersensitivity reaction to drugs.